TechTimes · Jun 2026
Coverage of Synchron’s planned pivotal clinical trial in 2026 and the significance of the trial for potential FDA approval.
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Synchron is a neurotechnology company pioneering interventional brain-computer interfaces (BCIs). Its first product, Stentrode™, is a minimally invasive implantable BCI delivered via the jugular vein that aims to restore communication, independence, and agency for people living with paralysis.
Primary product
Stentrode™ implantable brain-computer interface (BCI)
Founded
2016
Headquarters
Brooklyn, New York, United States
Team size
70-80
Industry
Medical Equipment Manufacturing
Sub-industry
Neurotechnology / implantable brain-computer interfaces
Offices
New York City (Soho, cognition lab)
San Diego, California
Melbourne, Australia
Campbell
Business model
medical device development
clinical-stage therapeutics / neurotechnology
B2B2C via hospital/clinical commercialization
Funding
People & investors
Leadership
CEO & Co-founder
Founding Director / Chief Innovation Officer
Chairman of the Board
Amos Meltzer
Chief Legal Officer
Kurt Haggstrom
Chief Commercial Officer
Riki Banerjee
Chief Technology Officer
Andy Rasdal
Chief of Staff
Mark Brister
VP R&D
Investors
Alumni Ventures
ARCH Ventures
Australian National Reconstruction Fund (NRF)
Bezos Expeditions
Double Point Ventures
Gates Frontier
Greenoaks
IQT
K5 Global
Khosla Ventures
METIS
Moore Strategic Ventures
NTI
Project X
Protocol Labs
Qatar Investment Authority (QIA)
Reliance Digital Health Limited
T.Rx Capital
University of Melbourne
Work & culture
The company emphasizes patient-first work, first-principles thinking, direct patient interaction, and open science. Careers pages describe an academic-style environment with weekly research seminars and multidisciplinary teams across engineering, science, medicine, and operations.
Product & market
Pricing
Not publicly disclosed; likely clinical-stage medical device commercialization model.
Differentiators
- —No open brain surgery; catheter/jugular-vein delivery
- —First product is a minimally invasive endovascular BCI
- —Open-science research posture with peer-reviewed publications
- —Clinical-trial validated product in the USA and Australia
- —Focus on restoring communication and agency for paralysis patients
Technology
implantable BCI
Stentrode electrode array
endovascular / catheter-based delivery
neural signal modeling
machine learning
AI / cognitive AI
Apple-native software
real-time neural data pipelines
closed-loop neurofeedback
wireless telemetry
cleanroom production
Customers
people living with paralysis
people with motor impairment
clinical trial participants
patients with severe paralysis or ALS
healthcare providers / clinical research sites
Competitors
Neuralink
other implantable BCI / neurotechnology companies
Scale & contact
Estimated revenue
USD 70M-$80M
Latest news
International Hospital · Jun 2026
Describes Synchron’s integration of OpenAI-generated chat features into its BCI platform for users with severe paralysis.
Business Wire · Nov 2025
Synchron announced a $200 million Series D led by Double Point Ventures, bringing total funding to $345 million and accelerating commercialization of Stentrode and next-generation interfaces.
Forbes Australia · Nov 2025
Coverage of the Series D round and Australia’s National Reconstruction Fund participation, highlighting Synchron’s commercial and clinical ambitions.
MobiHealthNews · Nov 2025
Reports the Series D financing and notes the company will expand operations in New York and San Diego to support trials and commercialization.
Jobs and careers at Synchron
0 jobs at Synchron
No open positions
Check back later for new openings